Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11184576 | 1.00 | CA5A (0.55) | — | |
| Piperazine SCHEMBL27978492 | 0.96 | TSHR (0.50) | — | |
| Sulfuric Acid SCHEMBL6099988 | 0.96 | TSHR (0.50) | — | |
| Sulfuric Acid SCHEMBL6099992 | 0.96 | TSHR (0.50) | — | |
| Sulfuric Acid SCHEMBL8300104 | 0.96 | TSHR (0.50) | — | |
| Piperazine SCHEMBL2445779 | 0.96 | TSHR (0.50) | — | |
| Sulfuric Acid SCHEMBL1326427 | 0.96 | — | — | |
| Sulfuric Acid SCHEMBL8291975 | 0.96 | TSHR (0.50) | — | |
| Piperazine SCHEMBL5875243 | 0.96 | TSHR (0.50) | — | |
| Sulfuric Acid SCHEMBL6260312 | 0.96 | TSHR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115845822-B | Adsorption material for removing blood cytokines and preparation method thereof | 佛山市博新生物科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-109422374-B | Advanced treatment method and system for biochemical effluent of leveling liquid | 宝山钢铁股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-107281793-A | Filter assemblies | 曼·胡默尔有限公司 | 2017-10-24 | — | — | CN | disclosed |
| CN-107057672-A | It is acidified water filling Swelling-resistant shrinking and swelling agent and preparation method thereof | 中国海洋石油总公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-106103659-A | Composition for removing sulfur-containing compound | 株式会社可乐丽 | 2016-11-09 | — | — | CN | disclosed |
| US-8445017-B2 | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof | EGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| CN-101094652-B | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof | EXPRESSION GENETICS INC | 2011-05-25 | — | — | CN | disclosed |
| US-20090226392-A1 | Phosphate-Binding Polymers for Oral Administration | GELTEX, INC. | 2009-09-10 | — | — | US | disclosed |
| US-7459151-B2 | Phosphate-binding polymers for oral administration | GENZYME CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1807054-A4 | BIODEGRADABLE CROSS-LINKED CATIONIC MULTI-BLOCK COPOLYMERS FOR GENE DELIVERY AND METHODS OF MAKING THEREOF | EXPRESSION GENETICS INC (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-1999022744-A1 | USE OF ALIPHATIC POLYAMINES FOR REDUCING OXALATE | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998042355-A1 | PHOSPHATE-BINDING POLYMERS COMBINED WITH A CALCIUM SUPPLEMENT FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| EP-0831857-A2 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5667775-A | TREATMENT OF HYPERPHOSPHATEMIA, ION EXCHANGING, CATIONIC POLYMERS, REMOVAL OF PHOSPHATE FROM GASTROINTESTINAL TRACT | GELTEX PHARMACEUTICALS, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1996039156-A2 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996021454-A1 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0716606-A1 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5496545-A | ALLYLAMINE POLYMERS, OPTIONALLY N-ALKYL-, ALKYLAMINO- OR ARYL-SUBSTITUTED, OR THEIR SALTS OR QUATERNARY DERIVATIVES | GELTEX PHARMACEUTICALS, INC. (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1995005184-A2 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| US-3951741-A | Process and apparatus for the synthesis of peptides by use of n-carboxyanhydrides | PFAENDER PETER | 1976-04-20 | — | — | US | disclosed |